

Nuformix plc
("Nuformix", the "Company" or the "Group")

Directorate Change

Cambridge, UK – 10 February 2021: Nuformix plc (LSE:NFX), announces that Dr Chris Blackwell has resigned as Non-Executive Chairman and Director of the Company with immediate effect due to personal reasons that require his immediate attention.

A process to appoint a new Non-Executive Chairman will start immediately.

Dr Anne Brindley, CEO of Nuformix, said: "Along with the rest of the Board, I would like to thank Chris for his contribution to the Company and we give him our very best wishes. I have enjoyed working closely with Chris and I am excited about driving the business forward with the significant value and opportunity that is in the existing pipeline. I look forward to being able to communicate in more detail the Company's plans and strategic priorities and our approach to create value for shareholders, in the coming weeks."

Enquiries:

Nuformix plc

Dr Anne Brindley, CEO

Fleur Wood, Investor Relations

Email: fleur.wood@nuformix.com

+44 (0)1223 627222

Allenby Capital Limited

Tim Sohal / Matt Butlin (Sales and Corporate
Broking)

Nick Athanas (Corporate Finance)

+44 (0)203 328 5656

About Nuformix

Nuformix is a pharmaceutical development company with a current focus in fibrosis and oncology. It is focused on unlocking the therapeutic potential and value of known drugs by repurposing them and developing them into novel medicines and in doing so creating additional commercial opportunities. The model of repurposing is enabled by Nuformix's expertise in the discovery of new forms of known drugs that allow Nuformix to file patent applications and get patent protection for its assets.

Nuformix plc shares are traded on the London Stock Exchange's Official List under the ticker: NFX. For more information, please visit www.nuformix.com.